NewAmsterdam Pharma Company N.V.NAMSNASDAQ
Loading
Operating Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+32.7%
5Y CAGR+106.4%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+32.7%/yr
Annual compound
5Y CAGR
+106.4%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
37.4x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
PeriodValueYoY Change
2025$248.13M+11.8%
2024$221.85M+12.6%
2023$197.06M+85.5%
2022$106.25M+203.8%
2021$34.98M+427.4%
2020$6.63M-